| Dr Susie Warren Lynn, MD | |
|
9238 Madison Blvd, Building 1, Suite 200, Madison, AL 35758-9100 | |
| (256) 774-7300 | |
| (256) 774-5300 |
| Full Name | Dr Susie Warren Lynn |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 9238 Madison Blvd, Madison, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598814402 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 16543 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Susie Warren Lynn, MD 6767 Old Madison Pike Nw, Building 4, Suite 400, Huntsville, AL 35806-2172 Ph: (256) 922-6675 | Dr Susie Warren Lynn, MD 9238 Madison Blvd, Building 1, Suite 200, Madison, AL 35758-9100 Ph: (256) 774-7300 |
News Archive
A study led by the University of Kentucky researcher Elaine Wittenberg-Lyles found that hospice family caregivers are "second order patients" themselves and require their own unique care needs.
Chesapeake IRB the leading provider of technology enabled independent institutional review board ("IRB") services to the clinical research industry, is pleased to announce it has been acquired by Linden Capital Partners, a Chicago-based healthcare private equity firm that invests world-class resources in exceptional healthcare companies.
The dermatological impact of COVID-19 is a burning topic at EADV's 2021 Spring Symposium. New research presented today highlights the effect that stringent hand hygiene during the pandemic has had on hand skin health.
A family's bravery and generosity in the face of their son's death three years ago has enabled researchers to make an important new finding about the brain and its stem cells.
Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.
› Verified 1 days ago
Blair Chance, MD, MPH Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 7583 Wall Triana Hwy, Madison, AL 35757 Phone: 256-830-5777 |